<DOC>
	<DOCNO>NCT02925221</DOCNO>
	<brief_summary>This study part Health Canada approval requirement tolvaptan observational , non-interventional study ( NIS ) describe impact tolvaptan ADPKD-related burden illness measure set Patient Reported Outcome ( PRO ) Questionnaires . The study also describe time renal replacement therapy ( RRT ) , dialysis transplantation , long-term mortality rate cause ( i.e . renal hepatic ) , ADPKD patient treat tolvatan ( JINARC™ )</brief_summary>
	<brief_title>Canadian Medical Assessment JINARC™ Outcomes Registry</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>ADPKD patient ≥18 year old time tolvaptan initiation The treat physician must reach decision treat patient tolvaptan per Canadian Product Monograph prior independently solicit patient participate study The patient legal guardian must sign informed consent indicate understand study allow use anonymous data purpose study The patient comprehend refuse sign inform consent The patient contraindication use tolvaptan specified Canadian Product Monograph The patient condition , per judgment treat physician , prohibit participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Kidney Disease</keyword>
	<keyword>ADPKD-Related Outcome</keyword>
	<keyword>Quality Life</keyword>
</DOC>